imatinib mesylate has been researched along with Experimental Radiation Injuries in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fox, J; Haston, CK; Thomas, DM | 1 |
| Chung, EJ; Citrin, DE; Horton, JA; Hudak, KE; Mitchell, JB; Sowers, A; Thetford, A; White, AO | 1 |
2 other study(ies) available for imatinib mesylate and Experimental Radiation Injuries
| Article | Year |
|---|---|
Imatinib therapy reduces radiation-induced pulmonary mast cell influx and delays lung disease in the mouse.
Topics: Animals; Benzamides; Female; Gene Expression Regulation; Imatinib Mesylate; Lung; Lung Diseases; Mast Cells; Mice; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Radiation Dosage; Radiation Injuries, Experimental | 2010 |
Inhibition of radiation-induced skin fibrosis with imatinib.
Topics: Animals; Benzamides; Female; Fibrosis; Imatinib Mesylate; Mice; Mice, Inbred C3H; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiation Injuries, Experimental; Radiation-Protective Agents; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Skin; Transforming Growth Factor beta1 | 2013 |